Restricted accessResearch articleFirst published online 2016-01-22
Alterations in the Levels of Amyloid-β,Phospholipid Hydroperoxide,and Plasmalogen in the Blood of Patients with Alzheimer’s Disease: Possible Interactions between Amyloid-β and These Lipids
Aside from accumulation of amyloid-β (Aβ) peptide in the brain, Alzheimer’s disease (AD) has been reported as being associated with peroxidation of major phospholipids (e.g., phosphatidylcholine (PtdCho)) and degradation of antioxidative phospholipids (e.g., ethanolamine plasmalogen (PlsEtn)). In addition to its presence in the brain, Aβ is also found in blood; however, there is still little information about the levels of PtdCho hydroperoxide (PCOOH) and PlsEtn in the blood of patients with AD. In this study, by assuming a possible interaction among Aβ, PCOOH, and PlsEtn in blood circulation, we evaluated the levels of these molecules and correlations in blood samples that had been obtained from our former AD study for PCOOH measurement (Kiko et al., J Alzheimers Dis28, 593-600, 2012). We found that when compared to controls, plasma from patients with AD showed lower concentrations of PlsEtn species, especially PlsEtn bearing the docosahexaenoic acid (DHA) moiety. In addition, lower PlsEtn and higher PCOOH levels were observed in red blood cells (RBCs) of patients with AD. In both AD and control blood samples, RBC PCOOH levels tended to correlate with plasma levels of Aβ40, and each PlsEtn species showed different correlations with plasma Aβ. These results, together with in vitro data suggesting Aβ aggregation due to a decrease in levels of PlsEtn having DHA, led us to deduce that Aβ is involved in alterations in levels of PCOOH and PlsEtn species observed in the blood of patients with AD.
YounkinSG (1995) Evidence that Aβ42 is the real culprit in Alzheimer’s disease. Ann Neurol37, 287–288.
2.
de la TorreJC (2004) Is Alzheimer’s disease a neurodegenerative or a vascular disorder? Data, dogma, and dialectics. Lancet Neurol3, 184–190.
3.
SelkoeDJ (2002) Alzheimer’s disease is a synaptic failure. Science298, 789–791.
4.
WirthsO, MulthaupG, BayerTA (2004) A modified β-amyloid hypothesis: Intraneuronal accumulation of the β-amyloid peptide–the first step of a fatal cascade. J Neurochem91, 513–520.
HulstaertF, BlennowK, IvanoiuA, SchoonderwaldtHC, RiemenschneiderM, De DeynPP, BancherC, CrasP, WiltfangJ, MehtaPD, IqbalK, PottelH, VanmechelenE, VandersticheleH (1999) Improved discrimination of AD patients using β-amyloid(1-42) and tau levels in CSF. Neurology52, 1555–1562.
7.
KikoT, NakagawaK, TsudukiT, FurukawaK, AraiH, MiyazawaT (2014) MicroRNAs in plasma and cerebrospinal fluid as potential markers for Alzheimer’s disease. J Alzheimers Dis39, 253–259.
8.
OlazaránJ, Gil-de-GómezL, Rodríguez-MartínA, Valentí-SolerM, Frades-PayoB, Marín-MuñozJ, AntúnezC, Frank-GarcíaA, Acedo-JiménezC, Morlán-GraciaL, Petidier-TorregrossaR, GuisasolaMC, Bermejo-ParejaF, Sánchez-FerroÁ, Pérez-MartínezDA, Manzano-PalomoS, FarquharR, RábanoA, CaleroM (2015) A blood-based, 7-metabolite signature for the early diagnosis of Alzheimer’s disease. J Alzheimers Dis45, 1157–1173.
9.
DeMattosRB, BalesKR, CumminsDJ, PaulSM, HoltzmanDM (2002) Brain to plasma amyloid-β efflux: A measure of brain amyloid burden in a mouse model of Alzheimer’s disease. Science295, 2264–2267.
10.
ScheunerD, EckmanC, JensenM, SongX, CitronM, SuzukiN, BirdTD, HardyJ, HuttonM, KukullW, LarsonE, Levy-LahadE, ViitanenM, PeskindE, PoorkajP, SchellenbergG, TanziR, WascoW, LannfeltL, SelkoeD, YounkinS (1996) Secreted amyloid β-protein similar to that in the senile plaques of Alzheimer’s disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer’s disease. Nat Med2, 864–870.
11.
MehtaPD, PirttilaT, MehtaSP, SersenEA, AisenPS, WisniewskiHM (2000) Plasma and cerebrospinal fluid levels of amyloid β proteins 1-40 and 1-42 in Alzheimer disease. Arch Neurol57, 100–105.
12.
van OijenM, HofmanA, SoaresHD, KoudstaalPJ, BretelerMM (2006) Plasma Aβ1-40 and Aβ1-42 and the risk of dementia: A prospective case-cohort study. Lancet Neurol5, 655–660.
13.
Graff-RadfordNR, CrookJE, LucasJ, BoeveBF, KnopmanDS, IvnikRJ, SmithGE, YounkinLH, PetersenRC, YounkinSG (2007) Association of low plasma Aβ42/Aβ40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Arch Neurol64, 354–362.
14.
MattsonMP, BegleyJG, MarkRJ, FurukawaK (1997) Aβ25-35 induces rapid lysis of red blood cells: Contrast with Aβ1-42 and examination of underlying mechanisms. Brain Res771, 147–153.
15.
MohantyJG, EckleyDM, WilliamsonJD, LaunerLJ, RifkindJM (2008) Do red blood cell-β-amyloid interactions alter oxygen delivery in Alzheimer’s disease?. Adv Exp Med Biol614, 29–35.
16.
JayakumarR, KusiakJW, ChrestFJ, DemehinAA, MuraliJ, WerstoRP, NagababuE, RaviL, RifkindJM (2003) Red cell perturbations by amyloid β-protein. Biochim Biophys Acta1622, 20–28.
17.
NakagawaK, KikoT, MiyazawaT, SookwongP, TsudukiT, SatohA, MiyazawaT (2011) Amyloid β-induced erythrocytic damage and its attenuation by carotenoids. FEBS Lett585, 1249–1254.
18.
NakagawaK, KikoT, KuriwadaS, MiyazawaT, KimuraF, MiyazawaT (2011) Amyloid β induces adhesion of erythrocytes to endothelial cells and affects endothelial viability and functionality. Biosci Biotechnol Biochem75, 2030–2033.
19.
KikoT, NakagawaK, TsudukiT, SuzukiT, AraiH, MiyazawaT (2012) Significance of lutein in red blood cells of Alzheimer’s disease patients. J Alzheimers Dis28, 593–600.
20.
KikoT, NakagawaK, SatohA, TsudukiT, FurukawaK, AraiH, MiyazawaT (2012) Amyloid β levels in human red blood cells. PLoS One7, e49620.
21.
GinsbergL, RafiqueS, XuerebJH, RapoportSI, GershfeldNL (1995) Disease and anatomic specificity of ethanolamine plasmalogen deficiency in Alzheimer’s disease brain. Brain Res698, 223–226.
GuanZ, WangY, CairnsNJ, LantosPL, DallnerG, SindelarPJ (1999) Decrease and structural modifications of phosphatidylethanolamine plasmalogen in the brain with Alzheimer disease. J Neuropathol Exp Neurol58, 740–747.
24.
MartinV, FabeloN, SantpereG, PuigB, MarinR, FerrerI, DiazM (2010) Lipid alterations in lipid rafts from Alzheimer’s disease human brain cortex. J Alzheimers Dis19, 489–502.
25.
GlaserPE, GrossRW (1994) Plasmenylethanolamine facilitates rapid membrane fusion: A stopped-flow kinetic investigation correlating the propensity of a major plasma membrane constituent to adopt an HII phase with its ability to promote membrane fusion. Biochemistry33, 5805–5812.
26.
MiyazawaT, KannoS, EitsukaT, NakagawaK (2006) Plasmalogen: A short review and newly-discovered functions. In Dietary Fats and Risk of Chronic Disease, YanagitaY, KnappHR, HuangYS, eds. AOCS Publishing, pp. 196–202.
YamashitaS, HonjoA, ArugaM, NakagawaK, MiyazawaT (2014) Preparation of marine plasmalogen and selective identification of molecular species by LC-MS/MS. J Oleo Sci63, 423–430.
30.
RoseHG, OklanderM (1965) Improved procedure for the extraction of lipids from human erythrocytes. J Lipid Res6, 428–431.
31.
FolchJ, LeesM, Sloane StanleyGH (1957) A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem226, 497–509.
YamashitaS, AbeA, NakagawaK, KinoshitaM, MiyazawaT (2014) Separation and detection of plasmalogen in marine invertebrates by high-performance liquid chromatography with evaporative light-scattering detection. Lipids49, 1261–1273.
34.
MaulikN, BagchiD, JonesR, CordisG, DasDK (1993) Identification and characterization of plasmalogen fatty acids in swine heart. J Pharm Biomed Anal11, 1151–1156.
35.
ShojiN, NakagawaK, AsaiA, FujitaI, HashiuraA, NakajimaY, OikawaS, MiyazawaT (2010) LC-MS/MS analysis of carboxymethylated and carboxyethylated phosphatidylethanolamines in human erythrocytes and blood plasma. J Lipid Res51, 2445–2453.
36.
IkedaS, TohyamaT, YoshimuraH, HamamuraK, AbeK, YamashitaK (2003) Dietary α-tocopherol decreases α-tocotrienol but not γ-tocotrienol concentration in rats. J Nutr133, 428–434.
37.
SuemotoT, OkamuraN, ShiomitsuT, SuzukiM, ShimadzuH, AkatsuH, YamamotoT, KudoY, SawadaT (2004) In vivo labeling of amyloid with BF-108. Neurosci Res48, 65–74.
38.
OnoK, YoshiikeY, TakashimaA, HasegawaK, NaikiH, YamadaM (2004) Vitamin A exhibits potent antiamyloidogenic and fibril-destabilizing effects in vitro. Exp Neurol189, 380–392.
SongF, PoljakA, ValenzuelaM, MayeuxR, SmytheGA, SachdevPS (2011) Meta-analysis of plasma amyloid-β levels in Alzheimer’s disease. J Alzheimers Dis26, 365–375.
45.
SeppäläTT, HerukkaSK, HänninenT, TervoS, HallikainenM, SoininenH, PirttiläT (2010) Plasma Aβ42 and Aβ40 as markers of cognitive change in follow-up: A prospective, longitudinal, population-based cohort study. J Neurol Neurosurg Psychiatry81, 1123–1127.
46.
MiyazawaT, SuzukiT, YasudaK, FujimotoK, MeguroK, SasakiH (1992) Accumulation of phospholipid hydroperoxides in red blood cell membranes in Alzheimer disease In Oxygen Radicals, YagiK, KondoM, NikiE, YoshikawaT, eds. Elsevier, pp. 327–330.
47.
SrikanthV, MaczurekA, PhanT, SteeleM, WestcottB, JuskiwD, MunchG (2011) Advanced glycation endproducts and their receptor RAGE in Alzheimer’s disease. Neurobiol Aging32, 763–777.
48.
FarooquiAA, HorrocksLA (1998) Plasmalogen-selective phospholipase A2 and its involvement in Alzheimer’s disease. Biochem Soc Trans26, 243–246.
49.
FarooquiAA, HorrocksLA (2006) Phospholipase A2-generated lipid mediators in the brain: The good, the bad, and the ugly. Neuroscientist12, 245–260.
50.
LeeJC, SimonyiA, SunAY, SunGY (2011) Phospholipases A2 and neural membrane dynamics: Implications for Alzheimer’s disease. J Neurochem116, 813–819.
51.
AstaritaG, JungKM, BerchtoldNC, NguyenVQ, GillenDL, HeadE, CotmanCW, PiomelliD (2010) Deficient liver biosynthesis of docosahexaenoic acid correlates with cognitive impairment in Alzheimer’s disease. PLoS One5, e12538.
OnoderaT, FutaiE, KanE, AbeN, UchidaT, KamioY, KanekoJ (2015) Phosphatidylethanolamine plasmalogen enhances the inhibiting effect of phosphatidylethanolamine on γ-secretase activity. J Biochem157, 301–309.
55.
KinoshitaM, OikawaS, HayasakaK, SekikawaA, NagashimaT, ToyotaT, MiyazawaT (2000) Age-related increases in plasma phosphatidylcholine hydroperoxide concentrations in control subjects and patients with hyperlipidemia. Clin Chem46, 822–828.
56.
NagashimaT, OikawaS, HirayamaY, TokitaY, SekikawaA, IshigakiY, YamadaR, MiyazawaT (2002) Increase of serum phosphatidylcholine hydroperoxide dependent on glycemic control in type 2 diabetic patients. Diabetes Res Clin Pract56, 19–25.
57.
SuzukiK, NakagawaK, MiyazawaT (2014) Augmentation of blood lipid glycation and lipid oxidation in diabetic patients. Clin Chem Lab Med52, 47–52.
58.
AsaiA, OkajimaF, NakajimaY, NagaoM, NakagawaK, MiyazawaT, OikawaS (2011) Involvement of Rac GTPase activation in phosphatidylcholine hydroperoxide-induced THP-1 cell adhesion to ICAM-1. Biochem Biophys Res Commun406, 273–277.
59.
LanJ, LiuJ, ZhaoZ, XueR, ZhangN, ZhangP, ZhaoP, ZhengF, SunX (2015) The peripheral blood of Aβ binding RBC as a biomarker for diagnosis of Alzheimer’s disease. Age Ageing44, 458–464.
60.
WeisserM, ViethM, StolteM, RiedererP, PfeufferR, LeblhuverF, SpitellerG (1997) Dramatic increase of α-hydroxyaldehydes derived from plasmalogens in the aged human brain. Chem Phys Lipids90, 135–142.
61.
BravermanNE, MoserAB (2012) Functions of plasmalogen lipids in health and disease. Biochim Biophys Acta1822, 1442–1452.
62.
LiuYH, WangYR, XiangY, ZhouHD, GiuntaB, Mañucat-TanNB, TanJ, ZhouXF, WangYJ (2015) Clearance of amyloid-beta in Alzheimer’s disease: Shifting the action site from center to periphery. Mol Neurobiol51, 1–7.
63.
KatoS, NakagawaK, SuzukiY, AsaiA, NagaoM, NagashimaK, OikawaS, MiyazawaT (2015) Liquid chromatography-tandem mass spectrometry determination of human plasma 1-palmitoyl-2-hydroperoxyoctadecadienoyl-phosphatidylcholine isomers via promotion of sodium adduct formation. Anal Biochem471, 51–60.
